We had the pleasure of meeting with Ethel Weld (Johns Hopkins University School of Medicine, Baltimore, MD, US) to discuss long acting cabotegravir in HIV prophylaxis.
Part 2 of the discussion can be viewed here.
The abstract entitled: ‘Distribution of long-acting (LA) cabotegravir (CAB) in plasma, mucosal tissues, and associated fluids after a single ultrasound-guided intramuscular (IM) injection in healthy adult participants’ (OA04.03) was presented at the HIVR4P Virtual Conference 2021, 27 January 2021.
Questions:
- Why is there a need for long acting injectable drugs in HIV prophylaxis? (0:20)
- What is known about the efficacy and acceptability of long-acting cabotegravir (CAB LA) in HIV prophylaxis? (4:00)
Disclosures: Ethel Weld has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed in coverage of the HIVR4P 2021 Virtual Meeting.
